ADHD in the United Kingdom 2026
Attention deficit hyperactivity disorder is one of the most common neurodevelopmental conditions in the UK, and in 2026 it is also one of the most structurally neglected ones. NHS Digital estimates that approximately 2.5 million people in England alone have ADHD — including those without a formal diagnosis — based on NICE prevalence rates of 5% for children and 3–4% for adults. Extrapolated to the full UK population, ADHD UK puts the total UK figure at over 3 million people. Yet only 0.32% of 9 million UK GP records had a recorded ADHD diagnosis as of 2025, according to data cited by the Priory Group. That means roughly only 1 in 9 people with ADHD in the UK carries a formal diagnosis. The condition is not rare. Access to assessment is. The gap between those who have ADHD and those who have been through any formal diagnostic process is one of the defining features of the UK’s current public health situation around neurodevelopmental conditions — and it has direct consequences for employment, mental health, education, and the criminal justice system.
The NHS England Independent ADHD Taskforce, commissioned in 2024 and publishing both its interim report in June 2025 and its final report in November 2025, put the economic cost of untreated ADHD at £17 billion per year to the UK economy — through reduced tax contributions, greater reliance on state benefits, higher rates of NEET status, long-term unemployment, and higher costs across health, social care, and criminal justice. That figure exists alongside a system where only 25% of children and 15% of adults with ADHD receive pharmacological treatment, despite research showing that 70–90% of those who meet diagnostic criteria benefit from medication. The NHS Taskforce was blunt about this in its plain English summary: “Only 25% of children and 15% of adults with ADHD get medication. This is far too low.” The Taskforce’s 15 recommendations, published in November 2025 and responded to by NHS England the same day, called for systemic changes across health, education, employment, and the criminal justice system. Whether those changes materialise is the question that will define the next decade of ADHD care in the UK.
Key Interesting Facts: ADHD in the UK 2026
ADHD IN THE UK — AT A GLANCE (2026)
=====================================
ESTIMATED ADHD POPULATION:
England (NHS Digital, May 2026) ████████████████████████████████ ~2,492,000
UK total (extrapolated, ADHD UK) ████████████████████████████████ ~3,000,000+
Of which children (5–24) ████████████░░░░░░░░░░░░░░░░░░░░ ~741,000 (29.7%)
Of which adults ████████████████████████░░░░░░░░ ~1,751,000 (70.3%)
DIAGNOSIS AND TREATMENT REALITY:
Have formal diagnosis (est.) ████░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ~1 in 9 only
Children receiving medication ████████░░░░░░░░░░░░░░░░░░░░░░░░ 26.6% (NICE est.)
Adults receiving medication ████░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 15.6% (NICE est.)
Would benefit from medication ██████████████████████████████░░ 70–90%
WAITING LIST CRISIS (England):
Open referrals — March 2026 ████████████████████████████████ 683,088 people
Open referrals — December 2025 ████████████████████████████████ 735,157 people
Open referrals — March 2025 ████████████████████████░░░░░░░░ 549,000 people
Waiting > 1 year (adults, Dec 2025) ████████████████████████████░░░░ 61.6%
NHS average wait (England, 2026) ████████████████████████░░░░░░░░ 2–8 years by region
| Fact | Figure | Source / Date |
|---|---|---|
| Estimated ADHD population — England | ~2,492,000 (incl. those without diagnosis) | NHS Digital ADHD Management Information, May 2026 |
| Estimated ADHD population — England (Nov 2025) | ~2,506,000 | NHS Digital, November 2025 |
| Estimated ADHD population — UK total (extrapolated) | ~3+ million | ADHD UK, based on NHS Digital England data, January 2026 |
| Children and young people (5–24) with ADHD — England | ~741,000 | NHS Digital, May 2026 |
| NICE adult ADHD prevalence estimate | 3–4% of adults | NICE guideline NG87; NHS Digital |
| NICE child/young person ADHD prevalence estimate | 5% of children and young people | NICE guideline NG87 |
| UK GP records with a recorded ADHD diagnosis (2025) | Only 0.32% of ~9 million UK GP records | Priory Group citing GP data, 2025 |
| Share of ADHD population with a formal diagnosis | Only 1 in 9 (approximately 11%) | Priory Group / ADHD UK |
| Open referrals for possible ADHD assessment — March 2026 | 683,088 (up to) | NHS Digital ADHD Management Information, May 2026 |
| Open referrals — December 2025 | 735,157 | NHS Digital, February 2026 |
| Open referrals — March 2025 (comparison) | ~549,000 | NHS Digital, May 2025 |
| New referrals recorded in December 2025 alone | 18,915 in one month | NHS Digital / House of Commons Library |
| Adults waiting more than 1 year — December 2025 | 61.6% of all adult open referrals | NHS Digital / House of Commons Library |
| Children waiting more than 1 year — December 2025 | ~66% (two thirds) of child open referrals | NHS Digital / House of Commons Library |
| Adults seen within 13 weeks — December 2025 | Only 10.2% | NHS Digital / House of Commons Library |
| Children seen within 13 weeks — December 2025 | Only 9% | NHS Digital / House of Commons Library |
| NHS average adult ADHD wait (England, 2026) | 2–8 years depending on region; average 3.2 years across England | ADHD Assessment Compare (April 2026); WeCovr (2026) |
| Longest documented NHS waits | 5–7 years in Kent, Sussex, parts of London | WeCovr 2026 |
| Average wait at TEWV NHS Trust | 618 days (FOI response, June 2025) | BBC News |
| Clearing current backlog — estimated time | Over 8 years at current rate | BBC Verify / ADHD-360 briefing |
| Children receiving pharmacological treatment (UK, 2025) | 26.6% of estimated ADHD children | UK ADHD Treatment Rates regional variation model, French et al. 2025 |
| Adults receiving pharmacological treatment (UK, 2025) | 15.6% of estimated ADHD adults | French et al. 2025 |
| Research estimate for medication benefit | 70–90% of those meeting diagnostic criteria benefit from medication | NHS Taskforce Plain English summary, 2025 |
| Estimated annual economic cost of untreated ADHD to UK | £17 billion | NHS England Independent ADHD Taskforce Part 1, June 2025 |
| ADHD prescriptions increase — adults 2023/24 to 2024/25 | Nearly one-quarter (25%) increase | NHS BSA data, July 2025; Pharmaceutical Journal, Dec 2025 |
| ADHD referrals increase in last decade | Over 400% | ADHD Assessment Compare, April 2026 |
| Dedicated ADHD review — announced December 2025 | Independent review into mental health, ADHD, and autism launched by Health Secretary Wes Streeting | Pharmaceutical Journal, December 5, 2025 |
Source: NHS Digital ADHD Management Information (May 2026, February 2026, November 2025); House of Commons Library FAQ: ADHD statistics England (June 2026); NHS England Independent ADHD Taskforce Part 1 (June 2025) and Part 2 (November 2025); NICE guideline NG87; ADHD UK (January 2026); Priory Group (2025); French et al. UK ADHD Treatment Rates 2025; Pharmaceutical Journal (December 2025)
These numbers sit at the intersection of a very common condition and a very underperforming system. The 41-item gap between estimated prevalence and recorded diagnoses is not a sign that the condition is being overestimated in research. NICE’s 3–4% adult figure is drawn from robust international epidemiology, and the Independent ADHD Taskforce — which included clinicians, people with lived experience, and NHS commissioners — cited it as credible and supported by consistent evidence. The gap means that the healthcare system’s recorded administrative prevalence of 0.74% in adult men and 0.20% in adult women falls far short of the estimated 3–4%. Roughly eight out of nine adults in the UK with ADHD have no formal diagnosis.
The £17 billion economic cost figure from the Taskforce is worth unpacking. It includes reduced tax contributions from people with ADHD who are unemployed or underemployed, higher welfare and benefits costs, increased health and social care utilisation, criminal justice costs driven by the higher-than-average ADHD prevalence in prisons and youth offending populations, and the family and relationship breakdowns that frequently follow years of undiagnosed and unsupported ADHD. The Taskforce’s model is an “invest to save” framing: addressing the treatment gap costs money upfront but reduces the downstream economic burden. The question it does not fully resolve — and one the Taskforce acknowledged — is how a stretched NHS actually finds the capacity to deliver that intervention at scale.
NHS ADHD Waiting Lists and Assessment Times in the UK 2026
NHS ADHD WAITING LIST GROWTH — ENGLAND (NHS DIGITAL DATA)
===========================================================
Open ADHD referrals over time:
Mar 2025 ██████████████████████████░░░░░░░ 549,000
Sep 2025 ████████████████████████████████░ 700,123
Dec 2025 ████████████████████████████████░ 735,157 ← recent high
Mar 2026 ████████████████████████████████░ 683,088
Note: March 2026 lower partly due to data submission timing;
trend trajectory remains substantially elevated
WAIT TIME DISTRIBUTION — ADULTS (December 2025):
< 13 weeks ██░░░░░░░░░░░░░░░░░░░ 10.2% (seen quickly)
13 weeks – 1 year ████████░░░░░░░░░░░░░ 28.2%
> 1 year ████████████████████░ 61.6% (majority — still waiting)
REGIONAL WAIT EXTREMES (2026):
Best areas ██░░░░░░░░░░░░░░░ Under 12 weeks (some London/South areas via RTC)
Average ██████████████░░░ ~2–3 years
Worst areas ████████████████░ 5–7 years (Kent, Sussex, some Midlands areas)
One NHS trust ████████████████░ 618 days average (TEWV FOI data, June 2025)
| Waiting List / Assessment Metric | Figure | Source / Date |
|---|---|---|
| Open ADHD referrals — March 2026 | Up to 683,088 people | NHS Digital ADHD Management Information, May 2026 |
| Of which in Mental Health Services Dataset (MHSD) | 505,845 referrals | NHS Digital, May 2026 |
| Open referrals — December 2025 | 735,157 | NHS Digital, February 2026 |
| Open referrals — September 2025 | 700,123 | NHS Digital, November 2025 |
| Open referrals — March 2025 | ~549,000 | NHS Digital, May 2025 |
| New ADHD referrals in December 2025 alone | 18,915 | NHS Digital |
| Adults on list > 1 year — December 2025 | 61.6% | House of Commons Library, June 2026 |
| Children on list > 1 year — December 2025 | ~66% (two thirds) | House of Commons Library |
| Adults seen within 13 weeks — December 2025 | 10.2% | NHS Digital |
| Children seen within 13 weeks — December 2025 | 9% | NHS Digital |
| Average NHS ADHD wait across England (adults, 2026) | Over 2 years average; 3.2 years cited by specialist clinic data | WeCovr 2026; ADHD Clinic March 2026 |
| Longest waits by area (2026) | 5–7 years in Kent, Sussex, and parts of London | WeCovr, January 2026 |
| Average wait — TEWV NHS Trust | 618 days (FOI response, June 2025) | BBC News |
| The Retreat Clinics (example NHS-commissioned) wait | 4 years from referral date (ADHD diagnosis); receiving 4–5x commissioned volume | The Retreat Clinics, February 2026 |
| Estimated time to clear current backlog | Over 8 years at current service capacity | BBC Verify; ADHD-360 briefing |
| Referral demand increase — last decade | Over 400% increase in referral demand | ADHD Assessment Compare, April 2026 |
| Some ICBs actively discouraged from RTC | NHS England seeking to limit Right to Choose in high-waitlist areas — restricting only viable alternative for many patients | ADHD-360 briefing, March 2025 |
| Concern flagged formally | NHS England received formal concerns about patients dying on waiting lists | ADHD-360 briefing |
| Independent review announced | Health Secretary Wes Streeting announced independent review into mental health, ADHD, and autism — December 4, 2025 | Pharmaceutical Journal |
Source: NHS Digital ADHD Management Information series (May 2026, February 2026, November 2025, May 2025); House of Commons Library (June 2026); WeCovr 2026; ADHD Clinic (March 2026); ADHD Assessment Compare (April 2026); BBC News (June 2025); ADHD-360 briefing (March 2025); Pharmaceutical Journal (December 2025)
The waiting list numbers are large enough that it is worth being specific about what they represent. The 683,088 open referrals in March 2026 are people who have already been referred by a GP — they are not simply wondering if they have ADHD. They have been through a GP appointment, been deemed clinically appropriate for specialist assessment, and entered the system. More than 61% of adults in that group have been waiting for over a year with no assessment date. A third will wait longer than three years. Clearing the current backlog at current NHS ADHD service capacity would take over eight years — which means the people referred today will, on average, be assessed sometime around 2033 or 2034.
The 400% increase in referral demand over the last decade colliding with a workforce of specialist psychiatrists, psychiatric nurses, and neurodevelopmental practitioners that takes years to train and has not grown proportionately is the structural core of the crisis. It is not a mystery why the list is long. What is less clear is how it gets shorter, given that the independent review announced by Health Secretary Wes Streeting in December 2025 was still in its early stages as of mid-2026. The Right to Choose pathway — under which NHS patients in England can request referral to any qualified provider for a first outpatient appointment, including independent ADHD clinics — has been the main safety valve for people who can navigate the system and access it. The attempt by some Integrated Care Boards to limit RTC in high-waitlist areas, flagged in the ADHD-360 briefing document as effectively trapping patients within failing NHS services, has been one of the more quietly contentious NHS policy stories of 2025–2026.
ADHD Prevalence by Age, Gender and Region in the UK 2026
ADHD ADMINISTRATIVE PREVALENCE — ENGLAND (NHS HEALTH SERVICE RECORDS)
=======================================================================
DIAGNOSED/RECORDED PREVALENCE:
Boys (children) ████████████░░░░░░░░░░░ 2.55% (administrative)
Girls (children) ████░░░░░░░░░░░░░░░░░░░ 0.67%
Men (adults) ████░░░░░░░░░░░░░░░░░░░ 0.74%
Women (adults) █░░░░░░░░░░░░░░░░░░░░░░ 0.20%
ESTIMATED TRUE PREVALENCE (NICE):
Children (all) ████████████████████░░░ 5%
Adults (all) ████████████░░░░░░░░░░░ 3–4%
GAP SUMMARY: Recorded rate is roughly 1/4 to 1/3 of estimated true prevalence
AGE OF DIAGNOSIS — GENDER GAP (2025 ECNP Congress research):
Women diagnosed on average: 28.96 years
Men diagnosed on average: 24.13 years
Difference: ~5 years later despite symptoms emerging at same childhood age
REGIONAL TREATMENT VARIATION (children, UK, French et al. 2025):
Best-performing ICB/health board: ██████████████████████████████ 60.6% treated
Worst-performing ICB/health board: ██████░░░░░░░░░░░░░░░░░░░░░░░░ 11.7% treated
Variation ratio: 4.6-fold difference between best and worst areas
| Demographic Metric | Figure | Source |
|---|---|---|
| Boys — administrative ADHD prevalence (England records) | 2.55% | NHS England ADHD Taskforce Part 1, citing McKechnie et al. 2023 |
| Girls — administrative ADHD prevalence | 0.67% | NHS England ADHD Taskforce Part 1 |
| Men (adults) — administrative ADHD prevalence | 0.74% | NHS England ADHD Taskforce Part 1 |
| Women (adults) — administrative ADHD prevalence | 0.20% | NHS England ADHD Taskforce Part 1 |
| NICE estimated true prevalence — children | 5% | NICE NG87; NHS Digital |
| NICE estimated true prevalence — adults | 3–4% | NICE NG87; NHS Digital |
| Under-recognition conclusion | Administrative prevalence is roughly 1/4 to 1/3 of estimated true prevalence; “under-recognition of ADHD remains a problem in England” | NHS Taskforce Part 1 |
| Average age of ADHD diagnosis — women | 28.96 years | 2025 European College of Neuropsychopharmacology Congress; WEF (March 2026) |
| Average age of ADHD diagnosis — men | 24.13 years | 2025 ECNP Congress |
| Diagnosis age gap — women vs. men | ~4.8 years later despite symptoms emerging at same point in childhood | 2025 ECNP Congress data |
| Adult women over 25 — medication prevalence change (2010–2023) | From 0.01% to 0.2% — more than 20-fold increase in 13 years | University of Oxford study; The Independent, January 2026 |
| Adult men over 25 — medication prevalence change (same period) | 15-fold increase | University of Oxford study |
| ADHD medication continuation at 1 year (UK patients) | Only 31% of UK patients remain on medication after 1 year | University of Oxford multi-country study |
| UK late diagnosis ASD/ADHD adult females (qualitative study, 2026) | Most participants reported waiting periods exceeding the norm and no follow-up care post-diagnosis | Wills & Chakraborty, Healthcare, January 14, 2026 |
| Cardiff University finding — late ADHD diagnosis in girls/women | Associated with increased mental health issues, self-harm, alcohol use, drug use | Cardiff University research, March 2026 |
| ADHD among NEET youth — England | 20–34% ADHD prevalence among NEET (not in education, employment or training) youth | ADHD Taskforce; Priory Group |
| Regional treatment variation — children (best vs. worst area) | Best area: 60.6% treated; worst: 11.7% — a 4.6-fold difference | French et al. UK ADHD Treatment Rates, 2025 |
| Regional treatment variation — adults (best vs. worst) | Best: 24.8%; worst: 8.6% | French et al. 2025 |
| Patients in most deprived areas receiving ADHD medicine | 63,400 patients — most deprived areas more likely to receive ADHD medicines | NHS BSA via Pharmacy Magazine |
Source: NHS England ADHD Taskforce Part 1 (June 2025); 2025 ECNP Congress / WEF (March 2026); University of Oxford multi-country study / The Independent (January 2026); Wills & Chakraborty, Healthcare (January 2026); Cardiff University (March 2026); French et al. Sciety (2025); NHS BSA / Pharmacy Magazine (August 2024)
The 4.6-fold difference in treatment rates between the best and worst NHS areas for children with ADHD is the sharpest illustration of what the NHS Taskforce called a “postcode lottery” in care. A child in the best-performing integrated care system has a 60.6% chance of receiving pharmacological treatment if they have ADHD. A child in the worst-performing area has an 11.7% chance. Both children have the same condition, the same clinical need, and the same NHS. The difference is geography.
The gender diagnosis gap is well-documented but still not well-acted on. Women being diagnosed nearly 5 years later than men on average — despite symptoms emerging at the same point in childhood — reflects a diagnostic framework that was historically built around how ADHD presents in boys: externalising, hyperactive, disruptive. Girls and women more frequently present with inattentive-predominant ADHD, which is less visible in classroom and clinical settings, easier to mask, and more often attributed to anxiety, depression, or personality. The Cardiff University research published in March 2026 found that late ADHD diagnosis in girls and women is associated with increased mental health difficulties, self-harm, alcohol use, and drug use. The University of Oxford study tracking adult ADHD medication use across five European countries found the UK had the highest relative increase in female adult prescriptions — a more than 20-fold increase between 2010 and 2023 — which reflects genuine catch-up on decades of under-diagnosis, not overdiagnosis.
ADHD Medication Prescriptions and Treatment in the UK 2026
ADHD PRESCRIPTION GROWTH — ENGLAND (NATIONAL TREND DATA)
==========================================================
ITEMS PRESCRIBED PER 1,000 PEOPLE (ENGLAND):
2019/20 ████████████████░░░░░░░░░░░░░░░░ 25 items/1,000 people
2023/24 ████████████████████████████░░░░ 41.55 items/1,000 people
Change: +66% total; average annual increase of 18% since pandemic
PRESCRIPTIONS BY DRUG (2023/24):
Methylphenidate (most prescribed) ████████████████████████████░░░░ 19 items/1,000 people
Lisdexamfetamine (fastest rising) █████████░░░░░░░░░░░░░░░░░░░░░░░ 8.68 items/1,000 people
(up from 2.86 in 2019/20 — +55% year-on-year)
REGIONAL INCREASE (annual rate, 2023/24):
London ████████████████████████████ 28% per year ← highest
SE England █████████████████████████░░░ 19.5%
NE & Yorkshire ████████████████████░░░░░░░░ 13% ← lowest
TOTAL CNS STIMULANT ITEMS PRESCRIBED (2023/24):
2.91 million items — +14.6% vs previous year
ADULT PRESCRIPTIONS (2023/24 to 2024/25):
Adults prescribed ADHD medication increased by nearly a QUARTER (+24%)
| Prescription Metric | Figure | Source / Date |
|---|---|---|
| ADHD prescription items — England 2019/20 | ~25 items per 1,000 people | BMJ Group / The Guardian (March 2025) |
| ADHD prescription items — England 2023/24 | 41.55 items per 1,000 people | BMJ Group; Guardian (March 2025) |
| Average annual prescription increase since pandemic | 18% per year | BMJ Group, March 2025 |
| Total CNS stimulant and ADHD drug items — 2023/24 | 2.91 million items (+14.6% on prior year) | NHS BSA; Pharmacy Magazine (August 2024) |
| Adults prescribed ADHD medication — 2024/25 vs 2023/24 | Nearly one-quarter (+~24%) increase | NHS BSA data, July 2025; Pharmaceutical Journal, December 2025 |
| Most prescribed drug — 2023/24 | Methylphenidate (brand names: Ritalin, Concerta, Delmosart) — 19 items/1,000 people | BMJ Group |
| Fastest rising drug — 2023/24 | Lisdexamfetamine — rose 55% year-on-year; 8.68 items/1,000 people (from 2.86 in 2019/20) | BMJ Group |
| Regional prescription variation — highest annual increase | London: 28% per year | BMJ Group |
| Regional prescription variation — lowest annual increase | NE England and Yorkshire: 13% per year | BMJ Group |
| Second highest annual increase | South East England: ~19.5% | BMJ Group |
| Most commonly prescribed age group (2023/24) | Young males aged 10–14 — just over 50,000 patients | NHS BSA; Pharmacy Magazine |
| Adult ADHD medication use over 25 — 2010 to 2023 | From 0.01% to 0.2% — 15-fold (males) and 20-fold (females) increase | University of Oxford; The Independent, January 2026 |
| Medication continuation at 1 year (UK) | Only 31% of UK patients remain on ADHD medication after 1 year | University of Oxford multi-country study |
| Patients in most deprived areas | 63,400 patients from most deprived areas prescribed ADHD medicines — deprivation association is significant | NHS BSA; Pharmacy Magazine |
| Patients with ADHD prescription in 2015/16 | ~106,000 patients | NHS BSA historical figures |
| Patients with ADHD prescription in 2021/22 | ~191,000 patients — 80% increase in 6 years | NHS BSA |
| Patients receiving nervous system stimulants/ADHD drugs in 2023/24 | ~278,000 patients | Priory Group citing NHS BSA |
| Social media’s role | Researchers flagged Instagram and TikTok content as potentially driving awareness and assessment-seeking; accuracy of content “can vary significantly” | BMJ Group; Guardian |
Source: BMJ Group (March 12, 2025); The Guardian (March 11, 2025); NHS BSA data published July 24, 2025; Pharmaceutical Journal (December 5, 2025); Pharmacy Magazine (August 2024); University of Oxford multi-country study, The Independent (January 2026)
The 18% annual prescription increase since the pandemic is a number that prompts two very different reactions depending on who is responding to it. ADHD UK chief executive Henry Shelford called it grounds for celebration: “We should celebrate this in the same way we celebrate increases in the identification and treatment of other medical conditions. It shows more people getting the help and support they need.” Researchers and clinicians have noted that the increase reflects genuine catch-up on decades of under-treatment — the NHS ADHD Taskforce itself stated plainly that only 15% of adults who meet diagnostic criteria are currently receiving treatment. The 70–90% figure for medication benefit is well-supported in the literature. So going from 15% treated to something closer to that range requires a substantial increase in prescriptions.
The lisdexamfetamine increase of 55% year-on-year is the largest single-drug movement in the data. Lisdexamfetamine (brand name Vyvanse in some markets, Elvanse in the UK) is a longer-acting stimulant increasingly preferred for adult ADHD due to its duration profile and lower abuse potential compared to shorter-acting formulations. Its steep rise partly reflects a maturing adult ADHD treatment population. The 31% medication continuation rate at 1 year in the UK is low. Less than a third of people who start ADHD medication are still on it a year later, which is a separate conversation from whether they should be — some people discontinue because they are doing well, others because of side effects, others because titration support has not been available on the NHS. The figure sits alongside the known shortage of psychiatrists able to manage the titration process, particularly for adult patients diagnosed via the Right to Choose or private pathways and then seeking NHS shared care agreements that some GP practices refuse to honour.
ADHD Adult Assessment in the UK: NHS vs Private Pathways 2026
ADULT ADHD ASSESSMENT PATHWAYS — UK 2026
==========================================
PATHWAY 1: STANDARD NHS REFERRAL
GP referral → waiting list → NHS specialist
Average wait: ███████████████████████████████ 2–8 years (regional variation)
Cost to patient: ░░░░░░░░░░░░░░░░░░ Free (if you can wait)
Disadvantage: Majority waiting > 1 year; some areas > 5 years; two-tier access
PATHWAY 2: RIGHT TO CHOOSE (NHS-FUNDED, INDEPENDENT PROVIDER)
GP referral → patient requests independent provider → NHS pays
Average wait: █████░░░░░░░░░░░░░░ Weeks to a few months (vs years)
Cost to patient: ░░░░░░░░░░░░░░░░░░ Free (NHS-funded)
Disadvantage: Some ICBs actively limiting access; varies by area
PATHWAY 3: PRIVATE ASSESSMENT
Patient self-pays → private clinic → assessment
Average wait: ██░░░░░░░░░░░░░░░░ 1–4 weeks (private fast-track: 21 days)
Cost to patient: ██████████████░░░░ £495–£1,200+ depending on provider
Shared care: May be eligible for NHS prescribing if GP accepts shared care agreement
Disadvantage: Cost; not all GPs accept shared care; creates inequity
| Assessment Pathway Metric | Figure | Source / Date |
|---|---|---|
| Standard NHS pathway — average wait (adults, 2026) | Over 2 years average nationally; 3.2 years cited by specialist clinic data | WeCovr January 2026; ADHD Clinic March 2026 |
| Standard NHS pathway — worst-case waits | 5–7 years in Kent, Sussex, parts of London | WeCovr 2026 |
| Right to Choose (RTC) — legal basis | Section 75 of NHS Act 2006: patients have right to choose any qualified provider for first outpatient appointment | NHS England; ClientForms March 2026 |
| Right to Choose — approximate wait | Weeks to a few months compared to years on standard list | ADHD Assessment Compare; ADHD UK |
| Right to Choose — cost | NHS-funded — no cost to patient | NHS England |
| RTC limitation concern | Some ICBs moving to limit patient numbers who can use RTC in high-waitlist areas — formally flagged as concern | ADHD-360 briefing, March 2025 |
| Private assessment — approximate cost | From ~£495 online to £1,200+ for comprehensive in-person | ADHD Assessment Compare, April 2026 |
| Private assessment — wait time | Typically 1–4 weeks for initial appointment; CQC-regulated fast-track: 21 days from inquiry to report | WeCovr; ADHD Clinic March 2026 |
| Shared care agreement — post-private diagnosis | Patient can move to NHS prescribing — but some GPs refuse shared care, requiring continued private prescribing | WeCovr 2026; ADHD UK |
| Two-tier system concern (NHS Taskforce) | “The most disadvantaged groups — highest risk, poorest households, those who have been in the criminal justice system — are least likely to be able to afford private assessment and treatment” | NHS Taskforce Part 2, November 2025 |
| Private assessment market growth | Driven by 2–8 year NHS waits; significant expansion of private ADHD clinic sector since 2021 | Industry data; ADHD Assessment Compare |
| Typical comprehensive assessment components | Clinical interview, screening tools (e.g. Conners, DIVA-5), cognitive testing, collateral history, report | CQC-regulated clinic standards |
| CQC regulation | Private ADHD clinics regulated by the Care Quality Commission — patients advised to verify CQC registration | ADHD Clinic March 2026; ClientForms |
| Titration (medication management) — private cost | Typically an additional separate cost after diagnosis; can be hundreds of pounds per follow-up | WeCovr 2026 |
Source: WeCovr (January 2026); ADHD Assessment Compare (April 2026); ADHD Clinic (March 2026); ClientForms (March 2026); NHS England; ADHD-360 briefing (March 2025); NHS Taskforce Part 2 (November 2025)
The Right to Choose pathway is the piece of the system that the NHS Taskforce described, and that patient advocacy organisations have been promoting, as the most equitable route through the current crisis. It is NHS-funded, it reduces wait times from years to months, and it is a legal right under the NHS Act 2006. In practice, navigating it requires a GP who knows it exists and is willing to process the referral in that way — and awareness among GPs is inconsistent. The NHS Taskforce Part 2 report was explicit that the postcode lottery affecting diagnostic rates extends to awareness and use of RTC.
The two-tier problem the Taskforce identified has a specific inequality structure. Private assessment costs starting from around £495 for an online assessment are accessible to people with mid-to-high incomes who can absorb that cost and the ongoing private prescription cost while waiting for a shared care agreement. They are not accessible to the 20–34% of NEET youth estimated to have ADHD, or to the significantly elevated proportion of people in the criminal justice system with the condition, or to the many adults living in deprivation whose undiagnosed ADHD is a contributing factor to the circumstances that already make their lives more difficult. The people with the most to gain from early diagnosis are precisely the people least likely to access it through the private route that most reliably delivers it in 2026.
ADHD Outcomes, Economic and Social Impact in the UK 2026
ADHD OUTCOMES — UK EVIDENCE SUMMARY
======================================
EDUCATION:
ADHD prevalence among NEET youth (England) ████████████████████████░░░░░░ 20–34%
Academic underachievement risk ████████████████████░░░░░░░░░░ Significantly elevated
EMPLOYMENT:
Higher rates of long-term unemployment ████████████████████░░░░░░░░░░ Documented
More likely to receive state benefits ████████████████░░░░░░░░░░░░░░ Documented
Women with ADHD — wage gap vs men with ADHD ████████████████░░░░░░░░░░░░░░ 28.2% less per year
CRIMINAL JUSTICE:
ADHD prevalence in prison populations ████████████████████████████░░ Elevated (est. 25–40%)
(General population adult prevalence: ████░░░░░░░░░░░░░░░░░░░░░░░░░░ 3–4%)
HEALTH AND MENTAL HEALTH:
Co-occurring mental health conditions ████████████████████████████░░ Very common
Suicide and self-harm risk ████████████████░░░░░░░░░░░░░░ Elevated
Substance misuse risk ████████████████░░░░░░░░░░░░░░ Elevated
ECONOMIC:
Cost of untreated ADHD to UK economy ████████████████████████████████ £17 billion/year
Healthcare costs over a decade (untreated) ████████████░░░░░░░░░░░░░░░░░░ £1.33bn–£5.78bn
| Outcome / Impact Metric | Figure | Source |
|---|---|---|
| Annual cost of untreated ADHD to UK economy | £17 billion | NHS England ADHD Taskforce Part 1, June 2025 |
| Cost components | Less tax contributions, state benefits, NEET status, long-term unemployment, health/social care, criminal justice costs | NHS Taskforce |
| Healthcare costs of untreated ADHD over a decade | £1.33 billion to £5.78 billion | ADHD-360 briefing; Loop Dynamics Group |
| ADHD prevalence among NEET youth in England | 20–34% | NHS Taskforce; Priory Group citing Taskforce data |
| Women with ADHD — wage gap vs. men with ADHD | Earn on average 28.2% less per year than men with ADHD — compounding gender and neurodivergent penalties | University of Kent research; WEF (March 2026) |
| Adults with ADHD — employment outcomes | Higher rates of long-term unemployment; more likely to be on state benefits; lower earnings | NHS Taskforce Part 1; Priory Group |
| ADHD and criminal justice | People with ADHD are overrepresented in prison and youth justice populations; ADHD Taskforce called for cross-sector data collection by ONS | NHS Taskforce |
| NHS Taskforce recommendation — criminal justice | ONS should routinely collect and analyse data on ADHD in health, education, workforce, and justice system | NHS Taskforce Part 1 |
| Co-occurring conditions | ADHD frequently co-occurs with anxiety, depression, ASD, learning difficulties; NHS reporting to expand to comorbidities from 2026 | Schoen Clinic; NHS Digital |
| Suicide risk | ADHD is associated with elevated suicide risk — cited by NHS Taskforce as a reason for urgent action | NHS Taskforce Part 1; ADHD-360 briefing |
| Substance misuse | Elevated rates of substance misuse in people with untreated ADHD | NHS Taskforce Plain English summary |
| Late diagnosis in girls — associated outcomes | Increased mental health problems, self-harm, alcohol use, drug use, teenage pregnancy, secondary school absences, higher hospital use | Cardiff University, March 2026; Medical Xpress |
| NHS Taskforce — 15 recommendations | Cross-government approach; school interventions; workforce training; quality standards for NHS and private; ADHD as priority in 10-Year Health Plan | NHS Taskforce Part 2, November 2025 |
| NHS England response to final report (November 6, 2025) | Already working with local systems to implement key recommendations; acknowledged “cross-sector services are under significant pressure” | NHS England, November 6, 2025 |
| Next step — Streeting review (December 2025) | Independent review into mental health conditions, ADHD, and autism — examining prevalence, trends, and inequalities | Pharmaceutical Journal, December 5, 2025 |
Source: NHS England ADHD Taskforce Part 1 (June 2025) and Part 2 (November 2025); NHS England response (November 6, 2025); Cardiff University (March 2026); WEF / University of Kent (March 2026); ADHD-360 briefing; Pharmaceutical Journal (December 5, 2025); Priory Group 2025
The £17 billion annual cost figure sits alongside a treatment system that is not structured to prevent those costs from accruing. The Taskforce’s logic is straightforward: ADHD that goes undiagnosed and untreated produces downstream costs across multiple government departments — DWP pays more in benefits to people who cannot hold employment, the MoJ processes more people through courts and prisons, NHS trusts treat more mental health crises, and schools manage more difficult-to-support young people without understanding the underlying condition. The “invest to save” case for earlier diagnosis and treatment is not contested by any party in the current debate. The contested question is how and by whom.
The 28.2% wage gap between women with ADHD and men with ADHD identified by the University of Kent is a number that deserves more attention than it gets. It is not a general gender pay gap figure — it is the gap between two people who both have the same neurodevelopmental condition. Women with ADHD are facing a compound disadvantage: they are diagnosed later, treated less often, and when in employment they earn substantially less than their male counterparts with the same condition. The WEF analysis published in March 2026 framed this as part of a broader hidden workforce cost — neurodivergent women working below their capability, managing undiagnosed conditions in environments that were not designed with them in mind, and producing economic outputs that are systematically undercounted because the systems that track workforce data were not designed to see this pattern either.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
